Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Vikram Deshpande

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4230-9308; OpenAlex author ID A5038972103. Sources: OpenAlex.

Their work

Papers
37 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
164
Papers, trials and grants by year

2012: 3 papers · 2013: 2 papers · 2014: 2 papers · 2015: 4 papers · 2016: 3 papers · 2017: 3 papers · 2018: none · 2019: 5 papers · 2020: 4 papers · 2021: 5 papers · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers

Papers 37

  1. Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.216713↗
  2. Disruption of cellular plasticity by repeat RNAs in human pancreatic cancer. Co-author DOI 10.1016/j.cell.2024.09.024↗
  3. Targeting ribosome biogenesis reinforces ERK-dependent senescence in pancreatic cancer. Co-author DOI 10.1080/15384101.2023.2278945↗
  4. Overexpression of integrin alpha 2 (ITGA2) correlates with poor survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jclinpath-2022-208176↗
  5. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Socie… Co-author DOI 10.1097/pas.0000000000001853↗
  6. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004585↗
  7. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-020-04897-9↗
  8. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Co-author DOI 10.1016/j.ccell.2021.07.007↗
  9. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. Co-author DOI 10.1093/jnci/djaa073↗
  10. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-1039↗
  11. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoad… Co-author DOI 10.1245/s10434-020-09444-z↗
  12. B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2020.1794359↗
  13. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003123↗
  14. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. Last author DOI 10.1111/his.14086↗
  15. Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. Co-author DOI 10.1158/1078-0432.ccr-18-1359↗
  16. Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. Co-author DOI 10.1016/j.cell.2019.05.012↗
  17. Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41379-018-0196-2↗
  18. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914915116↗
  19. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000002600↗
  20. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Co-author DOI 10.1245/s10434-019-07685-1↗
  21. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-0256↗
  22. Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.16841↗
  23. STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. Co-author DOI 10.18632/oncotarget.20833↗
  24. Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11605-016-3108-0↗
  25. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.biomaterials.2016.03.044↗
  26. SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b. Co-author DOI 10.1016/j.cell.2016.04.033↗
  27. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Co-author DOI 10.1038/nature14587↗
  28. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1097/sla.0000000000000867↗
  29. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-1591↗
  30. Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages. Co-author DOI 10.1371/journal.pone.0141392↗
  31. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable … Co-author DOI 10.1016/j.ijrobp.2014.03.034↗
  32. Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Co-author DOI 10.1073/pnas.1411679111↗
  33. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Co-author DOI 10.1097/sla.0b013e318263da2f↗
  34. KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. Co-author DOI 10.1172/jci64535↗
  35. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Co-author DOI 10.1016/j.surg.2012.05.020↗
  36. Cystic papillary pattern in pancreatic ductal adenocarcinoma: a heretofore undescribed morphologic pattern that mimics intraductal papillary mucinous carcinoma. Last author DOI 10.1097/pas.0b013e318249ce1c↗
  37. TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progression. First author DOI 10.1158/0008-5472.can-12-0634↗

Closest collaborators

The 25 strongest of 164 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David Tsai Ting · 15 shared papers, 2015–2024 · strength 1.35
  2. Keith D. Lillemoe · 14 shared papers, 2012–2022 · strength 1.10
  3. Cristina Rosa Ferrone · 13 shared papers, 2012–2023 · strength 1.04
  4. Theodore Sunki Hong · 12 shared papers, 2013–2022 · strength 0.92
  5. Carlos F. Fernandez-del Castillo · 13 shared papers, 2012–2022 · strength 0.91
  6. Nabeel M. Bardeesy · 12 shared papers, 2012–2024 · strength 0.83
  7. Motaz Qadan · 8 shared papers, 2019–2022 · strength 0.79
  8. Theodoros P. Michelakos · 8 shared papers, 2017–2024 · strength 0.76
  9. Jennifer Yon-Li Wo · 8 shared papers, 2014–2022 · strength 0.69
  10. Andrew Louis Warshaw · 9 shared papers, 2012–2021 · strength 0.63
  11. David P. Ryan · 9 shared papers, 2013–2022 · strength 0.62
  12. Cristina R. Ferrone · 9 shared papers, 2012–2020 · strength 0.54
  13. Azfar Neyaz · 5 shared papers, 2019–2021 · strength 0.42
  14. Lei Cai · 4 shared papers, 2017–2024 · strength 0.41
  15. Yurie Sekigami · 3 shared papers, 2021–2024 · strength 0.39
  16. Andrew Scott Liss · 4 shared papers, 2019–2024 · strength 0.38
  17. Onofrio A. Catalano · 3 shared papers, 2021–2022 · strength 0.35
  18. Kim C. Honselmann · 3 shared papers, 2019–2023 · strength 0.33
  19. Soldano Ferrone · 3 shared papers, 2017–2024 · strength 0.33
  20. Colin D. Weekes · 3 shared papers, 2021–2022 · strength 0.33
  21. Ulrich Friedrich Wellner · 3 shared papers, 2019–2023 · strength 0.32
  22. Carlos Fernández-del Castillo · 4 shared papers, 2017–2021 · strength 0.32
  23. Aparna R. Parikh · 3 shared papers, 2019–2022 · strength 0.31
  24. Janet E. Murphy · 4 shared papers, 2015–2022 · strength 0.29
  25. Tobias Keck · 2 shared papers, 2020–2023 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.